0A50.LSE Co-Diagnostics, Inc.
- Market cap
- -
- P/E
- 0.3x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0A50.LSE undervalued?
Graham numberThe Graham number of Co-Diagnostics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Co-Diagnostics, Inc. fundamental analysis
No fundamental analysis for Co-Diagnostics, Inc. yet.
Co-Diagnostics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C,…
Full company profileFinancial statements of Co-Diagnostics, Inc. are not available yet.
Co-Diagnostics, Inc. dividends
Co-Diagnostics, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 0.033333:1 on Jan 2, 2026.
Who owns Co-Diagnostics, Inc.
- Insiders 8.36%
- Institutions 7.47%
- Public & others 84.17%
- Free float 6.16M
Co-Diagnostics, Inc. company profile
- Company name
- Co-Diagnostics, Inc.
- Ticker
- 0A50.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 115
- Fiscal year end
- December
- Address
- 2401 S. Foothill Drive, Salt Lake City, UT, United States, 84109
- Phone
- 801 438 1036
- Website
- co-dx.com
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Co-Diagnostics, Inc. management
8- Mr. Dwight H. EganChairman, CEO & President · born 1953
- Mr. Richard David AbbottPresident · born 1972
- Mr. Daniel Bohrer C.P.A.Executive VP of Finance & Accounting and Principal Financial & Accounting Officer · born 1977
- Mr. David NielsenChief Operating Officer
- Mr. Christopher ThurstonChief Technology Officer
- Dr. Wesley C. Lindsey MBA, Ph.D.Chief Scientific Officer
- Dr. Mayuranki Almaula Ph.D.Senior Vice President of Overseas Operations & Strategic Alliances
- Mr. Seth EganChief Commercialization Officer & Strategy Officer